Pooling six trials with 3,459 adults, researchers saw bigger drops in weight, HbA1c and blood pressure at the higher dose. They flag small liver enzyme rises to monitor.
Recap by typeshit. Full story at Bioengineer.org.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
Doctors describe a rare esophageal perforation in a patient on semaglutide, a condition that can be deadly when diagnosis comes late.
Copenhagen researchers gave 108 adults with alcohol use disorder and obesity weekly shots or placebo alongside CBT, and blood tests backed up the drop.
Loading…